Kiniksa Pharmaceuticals Reports Strong 2025 Financials with 62% ARCALYST Revenue Growth and Return to Profitability
KNSA has more than doubled off its 52-week low of $18.255 on elevated volume (2.3× avg).
Summary
Kiniksa Pharmaceuticals filed its annual 10-K, confirming robust full-year 2025 financial results, including a 62% increase in ARCALYST net product revenue and a significant return to net income, while advancing its pipeline.
Key Events · Earnings and Guidance · KNSA
-
Full-Year 2025 Financial Performance
The company reported total revenue of $677.6 million for the year ended December 31, 2025, a 60% increase from $423.2 million in 2024. This confirms the robust financial results previously indicated in an 8-K filing on the same day.
-
ARCALYST Revenue Growth
Net product revenue from ARCALYST increased by 62% year-over-year, reaching $677.6 million in 2025 compared to $417.0 million in 2024, primarily driven by increased patient enrollment.
-
Return to Net Profitability
Kiniksa Pharmaceuticals achieved a net income of $59.0 million in 2025, a significant turnaround from a net loss of $43.2 million in 2024.
-
Increased Liquidity
Cash, cash equivalents, and short-term investments grew to $414.1 million as of December 31, 2025, up from $243.6 million at the end of 2024, providing strong financial runway.
Analysis · KNSA · Life Sciences
Kiniksa Pharmaceuticals' annual 10-K filing confirms a significant financial turnaround in 2025, driven by robust growth in ARCALYST net product revenue. The company successfully transitioned from a net loss in 2024 to a substantial net income in 2025, while also significantly increasing its cash and short-term investments. This report finalizes the strong preliminary financial results previously announced. Key pipeline assets like KPL-387 are progressing with Orphan Drug Designation and entry into Phase 2/3 trials, although the discontinuation of abiprubart development represents a setback. The overall financial health and continued pipeline advancement are positive indicators for the company's trajectory.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KNSA was trading at $42.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $18.26 to $49.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.